… The most common adverse events were diarrhea, nausea, fatigue, and rash, and these are
consistent with the known toxicity profiles of gefitinib 22 and vandetanib. Diarrhea and rash in …

… 500mg was associated with a higher degree of toxicity, as observed in the IDEAL studies,
which led to more dose reductions and treatment interruptions. The authors proposed that, the …

… , non-randomized, phase I, dose-escalating study, recruiting … and toxicity of single and
multiple oral doses of gefitinib in … animal toxicology studies and two clinical studies in healthy …

… on the results of randomized controlled studies. However, … clinical benefit could continue
the blinded study treatment. Dose interruptions of up to 14 days were allowed to manage toxicity…

… activity in monotherapy trials. We report a trial of adj gefitinib versus placebo after complete
resection of NSCLC. … Pts were randomized to gefitinib 250 mg or placebo daily x 2 years. …

… control, thereby improving outcomes in cancer treatment. In phase I clinical trials, gefitinib …
Clinically, gefitinib did not appear to increase the overall toxicity of chemotherapy. Based on …

… Further randomized clinical trials are needed. … nonrandomized phase II trial was performed
to evaluate the clinical efficacy and toxicity of sequential administration of gefitinib following a …

… The disappointing results observed in single-agent and combination clinical trials with gefitinib
… Six patients (21%) required a dose delay of gefitinib: 5 because of toxicity and 1 due to …

… gefitinib + pemetrexed used in this study showed a higher ORR and DCR, longer median
PFS and acceptable toxicity… However, most previous clinical trials failed to show a benefit for …

… In its initial clinical study, gefitinib caused radiographic … that underlie sensitivity and toxicity
to gefitinib. For example, EGFR … influence both response and toxicity following gefitinib. They …